High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.
Identifieur interne : 000149 ( Main/Exploration ); précédent : 000148; suivant : 000150High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.
Auteurs : Debbie L. Becker [Canada] ; Ayman Chit [États-Unis, Canada] ; Carlos A. Diazgranados [États-Unis] ; Michael Maschio [Canada] ; Eddy Yau [Canada] ; Michael Drummond [Royaume-Uni]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice, Canada, Femelle, Grippe humaine (), Humains, Mâle, Qualité de vie, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Économies.
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins inactivés.
- immunologie : Vaccins antigrippaux, Vaccins inactivés.
- Analyse coût-bénéfice, Canada, Femelle, Grippe humaine, Humains, Mâle, Qualité de vie, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Économies.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Canada, Cost Savings, Cost-Benefit Analysis, Female, Humans, Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Male, Quality of Life, Treatment Outcome, Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (immunology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Inactivated.
- chemical , immunology : Influenza Vaccines, Vaccines, Inactivated.
- prevention & control : Influenza, Human.
- Aged, Aged, 80 and over, Canada, Cost Savings, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Treatment Outcome.
Abstract
Seasonal influenza infects approximately 10-20% of Canadians each year, causing an estimated 12,200 hospitalizations and 3,500 deaths annually, mostly occurring in adults ≥65 years old (seniors). A 32,000-participant, randomized controlled clinical trial (FIM12; Clinicaltrials.gov NCT01427309) showed that high-dose inactivated influenza vaccine (IIV-HD) is superior to standard-dose vaccine (SD) in preventing laboratory-confirmed influenza illness in seniors. In this study, we performed a cost-utility analysis (CUA) of IIV-HD versus SD in FIM12 participants from a Canadian perspective. Healthcare resource utilization data collected in FIM12 included: medications, non-routine/urgent care and emergency room visits, and hospitalizations. Unit costs were applied using standard Canadian cost sources to estimate the mean direct medical and societal costs associated with each vaccine (2014 CAD). Clinical illness data from the trial were mapped to quality-of-life data from the literature to estimate differences in effectiveness between vaccines. Time horizon was one influenza season, however, quality-adjusted life-years (QALYs) lost due to death during the study were captured over a lifetime. A probabilistic sensitivity analysis (PSA) was also performed. Average per-participant medical costs were $47 lower and societal costs $60 lower in the IIV-HD arm. Hospitalizations contributed 91% of the total cost and were less frequent in the IIV-HD arm. IIV-HD provided a gain in QALYs and, due to cost savings, dominated SD in the CUA. The PSA indicated that IIV-HD is 89% likely to be cost saving. In Canada, IIV-HD is expected to be a less costly and more effective alternative to SD, driven by a reduction in hospitalizations.
DOI: 10.1080/21645515.2016.1215395
PubMed: 27669017
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.</title><author><name sortKey="Becker, Debbie L" sort="Becker, Debbie L" uniqKey="Becker D" first="Debbie L" last="Becker">Debbie L. Becker</name><affiliation wicri:level="1"><nlm:affiliation>a Optum , Burlington, Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>a Optum , Burlington, Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name><affiliation wicri:level="2"><nlm:affiliation>b Sanofi Pasteur , Swiftwater , PA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>b Sanofi Pasteur , Swiftwater , PA </wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>c Leslie Dan School of Pharmacy , University of Toronto , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>c Leslie Dan School of Pharmacy , University of Toronto , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Diazgranados, Carlos A" sort="Diazgranados, Carlos A" uniqKey="Diazgranados C" first="Carlos A" last="Diazgranados">Carlos A. Diazgranados</name><affiliation wicri:level="2"><nlm:affiliation>b Sanofi Pasteur , Swiftwater , PA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>b Sanofi Pasteur , Swiftwater , PA </wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Maschio, Michael" sort="Maschio, Michael" uniqKey="Maschio M" first="Michael" last="Maschio">Michael Maschio</name><affiliation wicri:level="1"><nlm:affiliation>a Optum , Burlington, Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>a Optum , Burlington, Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Yau, Eddy" sort="Yau, Eddy" uniqKey="Yau E" first="Eddy" last="Yau">Eddy Yau</name><affiliation wicri:level="1"><nlm:affiliation>d inVentiv Health Clinical , Burlington, Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>d inVentiv Health Clinical , Burlington, Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Drummond, Michael" sort="Drummond, Michael" uniqKey="Drummond M" first="Michael" last="Drummond">Michael Drummond</name><affiliation wicri:level="1"><nlm:affiliation>e Centre for Health Economics , University of York , Heslington, York , UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>e Centre for Health Economics , University of York , Heslington, York </wicri:regionArea><wicri:noRegion>York </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27669017</idno><idno type="pmid">27669017</idno><idno type="doi">10.1080/21645515.2016.1215395</idno><idno type="wicri:Area/Main/Corpus">000127</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000127</idno><idno type="wicri:Area/Main/Curation">000127</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000127</idno><idno type="wicri:Area/Main/Exploration">000127</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.</title><author><name sortKey="Becker, Debbie L" sort="Becker, Debbie L" uniqKey="Becker D" first="Debbie L" last="Becker">Debbie L. Becker</name><affiliation wicri:level="1"><nlm:affiliation>a Optum , Burlington, Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>a Optum , Burlington, Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name><affiliation wicri:level="2"><nlm:affiliation>b Sanofi Pasteur , Swiftwater , PA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>b Sanofi Pasteur , Swiftwater , PA </wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>c Leslie Dan School of Pharmacy , University of Toronto , Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>c Leslie Dan School of Pharmacy , University of Toronto , Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Diazgranados, Carlos A" sort="Diazgranados, Carlos A" uniqKey="Diazgranados C" first="Carlos A" last="Diazgranados">Carlos A. Diazgranados</name><affiliation wicri:level="2"><nlm:affiliation>b Sanofi Pasteur , Swiftwater , PA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>b Sanofi Pasteur , Swiftwater , PA </wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Maschio, Michael" sort="Maschio, Michael" uniqKey="Maschio M" first="Michael" last="Maschio">Michael Maschio</name><affiliation wicri:level="1"><nlm:affiliation>a Optum , Burlington, Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>a Optum , Burlington, Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Yau, Eddy" sort="Yau, Eddy" uniqKey="Yau E" first="Eddy" last="Yau">Eddy Yau</name><affiliation wicri:level="1"><nlm:affiliation>d inVentiv Health Clinical , Burlington, Ontario , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>d inVentiv Health Clinical , Burlington, Ontario </wicri:regionArea><wicri:noRegion>Ontario </wicri:noRegion></affiliation></author><author><name sortKey="Drummond, Michael" sort="Drummond, Michael" uniqKey="Drummond M" first="Michael" last="Drummond">Michael Drummond</name><affiliation wicri:level="1"><nlm:affiliation>e Centre for Health Economics , University of York , Heslington, York , UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>e Centre for Health Economics , University of York , Heslington, York </wicri:regionArea><wicri:noRegion>York </wicri:noRegion></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Canada</term><term>Cost Savings</term><term>Cost-Benefit Analysis</term><term>Female</term><term>Humans</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Quality of Life</term><term>Treatment Outcome</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Canada</term><term>Femelle</term><term>Grippe humaine ()</term><term>Humains</term><term>Mâle</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins inactivés (administration et posologie)</term><term>Vaccins inactivés (immunologie)</term><term>Économies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Canada</term><term>Cost Savings</term><term>Cost-Benefit Analysis</term><term>Female</term><term>Humans</term><term>Male</term><term>Quality of Life</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Canada</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Économies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Seasonal influenza infects approximately 10-20% of Canadians each year, causing an estimated 12,200 hospitalizations and 3,500 deaths annually, mostly occurring in adults ≥65 years old (seniors). A 32,000-participant, randomized controlled clinical trial (FIM12; Clinicaltrials.gov NCT01427309) showed that high-dose inactivated influenza vaccine (IIV-HD) is superior to standard-dose vaccine (SD) in preventing laboratory-confirmed influenza illness in seniors. In this study, we performed a cost-utility analysis (CUA) of IIV-HD versus SD in FIM12 participants from a Canadian perspective. Healthcare resource utilization data collected in FIM12 included: medications, non-routine/urgent care and emergency room visits, and hospitalizations. Unit costs were applied using standard Canadian cost sources to estimate the mean direct medical and societal costs associated with each vaccine (2014 CAD). Clinical illness data from the trial were mapped to quality-of-life data from the literature to estimate differences in effectiveness between vaccines. Time horizon was one influenza season, however, quality-adjusted life-years (QALYs) lost due to death during the study were captured over a lifetime. A probabilistic sensitivity analysis (PSA) was also performed. Average per-participant medical costs were $47 lower and societal costs $60 lower in the IIV-HD arm. Hospitalizations contributed 91% of the total cost and were less frequent in the IIV-HD arm. IIV-HD provided a gain in QALYs and, due to cost savings, dominated SD in the CUA. The PSA indicated that IIV-HD is 89% likely to be cost saving. In Canada, IIV-HD is expected to be a less costly and more effective alternative to SD, driven by a reduction in hospitalizations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27669017</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>12</Month></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.</ArticleTitle><Pagination><MedlinePgn>3036-3042</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2016.1215395</ELocationID><Abstract><AbstractText>Seasonal influenza infects approximately 10-20% of Canadians each year, causing an estimated 12,200 hospitalizations and 3,500 deaths annually, mostly occurring in adults ≥65 years old (seniors). A 32,000-participant, randomized controlled clinical trial (FIM12; Clinicaltrials.gov NCT01427309) showed that high-dose inactivated influenza vaccine (IIV-HD) is superior to standard-dose vaccine (SD) in preventing laboratory-confirmed influenza illness in seniors. In this study, we performed a cost-utility analysis (CUA) of IIV-HD versus SD in FIM12 participants from a Canadian perspective. Healthcare resource utilization data collected in FIM12 included: medications, non-routine/urgent care and emergency room visits, and hospitalizations. Unit costs were applied using standard Canadian cost sources to estimate the mean direct medical and societal costs associated with each vaccine (2014 CAD). Clinical illness data from the trial were mapped to quality-of-life data from the literature to estimate differences in effectiveness between vaccines. Time horizon was one influenza season, however, quality-adjusted life-years (QALYs) lost due to death during the study were captured over a lifetime. A probabilistic sensitivity analysis (PSA) was also performed. Average per-participant medical costs were $47 lower and societal costs $60 lower in the IIV-HD arm. Hospitalizations contributed 91% of the total cost and were less frequent in the IIV-HD arm. IIV-HD provided a gain in QALYs and, due to cost savings, dominated SD in the CUA. The PSA indicated that IIV-HD is 89% likely to be cost saving. In Canada, IIV-HD is expected to be a less costly and more effective alternative to SD, driven by a reduction in hospitalizations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Debbie L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>a Optum , Burlington, Ontario , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chit</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>b Sanofi Pasteur , Swiftwater , PA , USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Leslie Dan School of Pharmacy , University of Toronto , Ontario , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiazGranados</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>b Sanofi Pasteur , Swiftwater , PA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maschio</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a Optum , Burlington, Ontario , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yau</LastName><ForeName>Eddy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>d inVentiv Health Clinical , Burlington, Ontario , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drummond</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>e Centre for Health Economics , University of York , Heslington, York , UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01427309</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017046" MajorTopicYN="N">Cost Savings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Fluzone</Keyword><Keyword MajorTopicYN="Y">cost-effectiveness</Keyword><Keyword MajorTopicYN="Y">cost-utility</Keyword><Keyword MajorTopicYN="Y">high-dose inactivated influenza vaccine</Keyword><Keyword MajorTopicYN="Y">influenza</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27669017</ArticleId><ArticleId IdType="doi">10.1080/21645515.2016.1215395</ArticleId><ArticleId IdType="pmc">PMC5215371</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stat Med. 2003 Jun 30;22(12):1955-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12802815</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Sep 11;33(38):4988-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26212007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2015 Dec;15(12):1459-66</Citation><ArticleIdList><ArticleId IdType="pubmed">26362172</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Econ. 2001 Dec;10(8):779-87</Citation><ArticleIdList><ArticleId IdType="pubmed">11747057</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20798667</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2012 Jun 8;61(22):414-20</Citation><ArticleIdList><ArticleId IdType="pubmed">22672977</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Jun 28;25(27):5086-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17544181</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2013 Dec 13;62(49):997-1000</Citation><ArticleIdList><ArticleId IdType="pubmed">24336131</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Jan 29;33(5):734-41</Citation><ArticleIdList><ArticleId IdType="pubmed">25444791</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):473-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23760189</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Aug 14;371(7):635-45</Citation><ArticleIdList><ArticleId IdType="pubmed">25119609</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Infect. 2007 Oct;135(7):1109-16</Citation><ArticleIdList><ArticleId IdType="pubmed">17306052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Becker, Debbie L" sort="Becker, Debbie L" uniqKey="Becker D" first="Debbie L" last="Becker">Debbie L. Becker</name></noRegion><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name><name sortKey="Maschio, Michael" sort="Maschio, Michael" uniqKey="Maschio M" first="Michael" last="Maschio">Michael Maschio</name><name sortKey="Yau, Eddy" sort="Yau, Eddy" uniqKey="Yau E" first="Eddy" last="Yau">Eddy Yau</name></country><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name></region><name sortKey="Diazgranados, Carlos A" sort="Diazgranados, Carlos A" uniqKey="Diazgranados C" first="Carlos A" last="Diazgranados">Carlos A. Diazgranados</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Drummond, Michael" sort="Drummond, Michael" uniqKey="Drummond M" first="Michael" last="Drummond">Michael Drummond</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000149 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000149 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27669017
|texte= High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27669017" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |